Homoeopathic treatment of skin disease

Phase 3

Conditions: Health Condition 1: L400- Psoriasis vulgaris

Registration Number: CTRI/2023/07/055529

Lead Sponsor: ehru Homoeopathic Medical College & Hospital, Govt. of NCT of Delh

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Cases suffering from psoriasis vulgaris (ICD-10-CM diagnosis code L40.0) mainly affects mainly trunk and the extensor surfaces of the limbs and scalp for at least 3 months

2.Psoriasis of mild (PASI < 7, DLQI < 7) to moderate severity (PASI 7-15, DLQI 5-15; may be classified as severe when difficult-to-treat sites are affected or when there is a significant psychosocial impact)

3.Had not taken any treatment for the past 2 weeks

4.Those aged between 18 and 65 years

5.Participants of either sex

6.Literate patients who can read English, Hindi and/or Bengali. Illiterate participants will be interviewed by the investigators maintaining adequate privacy

Exclusion Criteria

1.Suffering from severe psoriasis (PASI > 15, independent of DLQI score)

2.Suffering from guttate, pustular, erythrodermic and annular varieties of psoriasis

3.Similar looking skin conditions â?? atopic and contact dermatitis, lichen planus, secondary syphilis, mycosis fungoides, tinea corporis, pityriasis rosea, etc.

4.Vulnerable population â?? unconscious, non-ambulatory, too sick for consultation, differently abled, terminally or critically ill subjects.

5.Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure

6.Pregnant and puerperal women, lactating mothers

7.Tobacco chewing and/or smoking, alcoholism, and/or any other form(s) of substance abuse and/or dependence

8.Self-reported immune-compromised state (e.g., HIV)

9.Undergoing homeopathic treatment for any chronic disease(s) within last 6 months

10.Simultaneous participation in any other clinical trial

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Psoriasis area & severity index (PASI)Timepoint: Baseline, every month, up to 6 months

Secondary Outcome Measures

Name	Time	Method
Dermatology life quality index (DLQI)Timepoint: Baseline, every month, up to 6 months;Psoriasis Disability Index (PDI)Timepoint: Baseline, every month, up to 6 months